Management of Alcohol Associated Liver Diseases: Review of Current Guidelines

Management of Alcohol-Associated Liver Disease (ALD): Review of Current Guidelines

Comprehensive Structured Summary

1. Main Clinical Topics Discussed

• Updated 2024 clinical practice guidelines on Alcohol-Associated Liver Disease (ALD), published in the *American Journal of Gastroenterology* — the first revision since 2018
• Epidemiology and rising burden of ALD in the United States
• Disease modifiers, co-factors, and genetic risk
• Diagnosis and management of Alcohol Use Disorder (AUD)
• Pharmacotherapy for AUD in the setting of liver disease
• Disease spectrum classification and staging of ALD
• Introduction of new nomenclature: MetALD, MASLD, MASH

2. Key Learning Points, Guidelines, and Recommendations

Guideline Structure:

• 21 formal recommendations + 34 summary statements
• Strength of recommendations: strong, weak, or conditional (consensus-based)
• Level of evidence: high to very low

Risk Factors and Co-factors (Recommendations 1–6):

• Smoking combined with alcohol use significantly increases cirrhosis risk
• Patients with obesity/metabolic syndrome should be advised to avoid alcohol entirely (no safe threshold defined); abstinence also reduces caloric intake
• High-risk groups requiring alcohol screening and counseling include:

- Patients with Hepatitis B or C co-infection (synergistic hepatotoxicity)

- Patients post gastric bypass surgery (significantly elevated AUD risk)

- Patients with relevant genetic polymorphisms (e.g., *PNPLA3*)

Screening and Brief Intervention (Recommendations 7–10):

• Screen for AUD at every clinical encounter
• Use the AUDIT-C (first 3 questions of full AUDIT): takes <30 seconds

- Score ≥3 (female) or ≥4 (male) = positive screen for AUD

• Provide brief intervention (10–15 seconds): educate on safe limits and harms of alcohol — evidence-based for improving outcomes
• Distinguish between DSM-5 AUD (social/functional impairment criteria, ≥2 of 11) and at-risk alcohol use (quantity-based, liver health–focused)

Pharmacotherapy for AUD:

• For alcohol withdrawal in hospitalized patients with decompensated cirrhosis or hepatic encephalopathy risk: prefer lorazepam or oxazepam (short-acting) over diazepam or chlordiazepoxide (long-acting benzodiazepines)

Disease Classification:

• Early ALD: steatosis, mild alcoholic hepatitis (bilirubin normal), fibrosis stage ≤2
• Advanced ALD: fibrosis stage 3–4, or clinical alcoholic hepatitis with jaundice (bilirubin >3 mg/dL)
• MetALD (new term): overlap of metabolic liver disease and ALD

- Female: 20–50 g/day alcohol = MetALD; <20 g = pure MASLD; >50 g = pure ALD

- Male: 30–60 g/day = MetALD; <30 g = pure MASLD; >60 g = pure ALD

3. Specific Clinical Data and Study Results Cited

• ALD now accounts for ~45% of all liver transplants in the US (~3,000–3,500/year, data from approximately 5 years prior, with numbers since increasing)
• ALD has **surpassed all other eti